(30 days)
Not Found
No
The document describes a standard antimicrobial susceptibility testing panel and instrumentation, with no mention of AI or ML in the device description, intended use, or performance studies. The focus is on the chemical and biological reactions and the reading of results by instrumentation or visually.
No.
This device is an in-vitro diagnostic (IVD) device used to determine the susceptibility of certain gram-positive bacteria to antimicrobial agents, not a therapeutic device for treating patients.
Yes
The device determines quantitative and/or qualitative antimicrobial agent susceptibility of bacterial colonies, which is a diagnostic function used to guide treatment by identifying the effectiveness of antibiotics against specific pathogens.
No
The device is a physical panel with dried antimicrobial agents that is inoculated with a bacterial suspension and incubated. While instrumentation is used to read the results, the core device is a physical diagnostic test panel, not software.
Based on the provided text, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The device is used to determine the susceptibility of microorganisms (bacteria) to antimicrobial agents. This is a classic function of an in vitro diagnostic device, as it involves testing biological samples (bacterial colonies) outside of the body to provide information for diagnosis and treatment decisions.
- Device Description: The description details a miniaturized broth dilution susceptibility test, which is a common method used in clinical microbiology laboratories for AST. This process is performed in vitro.
- Performance Studies: The performance studies compare the device's results to a reference method (CLSI frozen Reference panel), which is standard practice for validating IVD devices. The metrics reported (Essential Agreement) are also typical for AST IVDs.
The device is clearly designed to be used in a laboratory setting to analyze biological samples (bacterial cultures) to provide information about their characteristics (antimicrobial susceptibility), which directly aligns with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
To determine antimicrobial agent susceptibility
The MicroScan® Synergies plus® Gram-Positive MIC/Combo Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of rapidly growing aerobic and facultative anaerobic gram-positive staphylococci and enterococci. After inoculation, panels are incubated for 4.5 - 18 hours at 35℃ +/- 1℃, in a WalkAway® SI, or equivalent, and read by the MicroScan® Instrumentation. Additionally, the panels may be incubated in a non-CO2 incubator and the Antimicrobial Susceptibility Testing (AST) portions can be read visually, according to the Package Insert.
This particular submission is for the addition of the antimicrobial vancomycin, at concentrations of 0.25 to 64 ug/ml, to the test panel.
The gram-positive organisms which may be used for vancomycin susceptibility testing in this panel are:
- Enterococcus spp. (e.g., Enterococcus faecalis) .
- Staphylococcus spp. ●
- Staphylococcus aureus (including methicillin-resistant strains) .
- Staphylococcus epidermidis (including methicillin-resistant ● strains)
Product codes (comma separated list FDA assigned to the subject device)
LON, JWY
Device Description
MicroScan® Synergies plus Gram-Positive MIC/Combo Panels, utilizing both the MicroScan® Rapid Fluorogenic Identification and Dried Overnight Antimicrobial Susceptibility Testing (AST) technologies, are designed for use in determining quantitative antimicrobial agent susceptibility of colonies grown on solid media of rapidly growing and facultative anaerobic gram-positive staphylococci and enterococci.
The antimicrobial susceptibility tests are miniaturizations of the broth dilution susceptibility test that have been diluted in water and dehydrated. Various antimicrobial agents are diluted in water, buffer, or minute concentrations of broth, to concentrations bridging the range of clinical interest. Panels are rehydrated with Synergies plus® Pos Broth, after inoculation with a standardized suspension of the organism. After incubation in the WalkAway® SI System, or equivalent, for 4.5 -18 hours, the minimum inhibitory concentration (MIC) for the test organism is read by determining the lowest antimicrobial concentration showing inhibition of growth.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
The S. aureus data from the previously cleared vancomycin external evaluation (K060312) was compared to the performance of a CLSI frozen Reference panel utilizing the revised interpretative criteria (S ≤ 2. I = 4 -8. R ≥ 16). Challenge strains were compared to Expected Results determined prior to the evaluation.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The proposed MicroScan® Synergies plus® Gram-Positive MIC/Combo Panel demonstrated substantially equivalent performance when compared with a frozen Reference Panel, as defined in the FDA document "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA", dated March 5, 2007. The Premarket Notification (510[k]) presents data in support of the MicroScan® Synergies plus® Gram-Positive MIC/Combo Panel with vancomycin.
The Synergies plus Gram-Positive Panel demonstrated acceptable performance with an overall Essential Agreement of 97.6% for vancomycin when compared with the frozen Reference panel.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Essential Agreement of 97.6%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
MicroScan® Synergies plus® Gram-Positive MIC/Combo Panels
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1645 Fully automated short-term incubation cycle antimicrobial susceptibility system.
(a)
Identification. A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.(b)
Classification. Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.”
0
KO92919
OCT 2 3 2009
Page 1 of 1
510(k) Summary
510(k) Submission Information:
| Device Manufacturer: | Siemens Healthcare Diagnostics |
|---|---|
| Contact name: | Shannon Popson, Regulatory Affairs Senior Technical Specialist |
| Fax: | 916-374-3330 |
| Date prepared: | September 11, 2009 |
| Product Name: | Microdilution Minimum Inhibitory Concentration (MIC) Panels |
| Trade Name: | MicroScan® Synergies plus® Gram-Positive MIC/Combo Panels |
| Intended Use: | To determine antimicrobial agent susceptibility |
| 510(k) Notification: | Device Modification - Evaluation of Vancomycin (K060312) versus |
| aureus interpretive criteria (S ≤ 2, I = 4 -8, R ≥ 16). | |
| Predicate device: | MicroScan® Synergies plus® Gram-Positive MIC/Combo Panels |
510(k) Summary:
MicroScan® Synergies plus Gram-Positive MIC/Combo Panels, utilizing both the MicroScan® Rapid Fluorogenic Identification and Dried Overnight Antimicrobial Susceptibility Testing (AST) technologies, are designed for use in determining quantitative antimicrobial agent susceptibility of colonies grown on solid media of rapidly growing and facultative anaerobic gram-positive staphylococci and enterococci.
The antimicrobial susceptibility tests are miniaturizations of the broth dilution susceptibility test that have been diluted in water and dehydrated. Various antimicrobial agents are diluted in water, buffer, or minute concentrations of broth, to concentrations bridging the range of clinical interest. Panels are rehydrated with Synergies plus® Pos Broth, after inoculation with a standardized suspension of the organism. After incubation in the WalkAway® SI System, or equivalent, for 4.5 -18 hours, the minimum inhibitory concentration (MIC) for the test organism is read by determining the lowest antimicrobial concentration showing inhibition of growth.
The proposed MicroScan® Synergies plus® Gram-Positive MIC/Combo Panel demonstrated substantially equivalent performance when compared with a frozen Reference Panel, as defined in the FDA document "Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA", dated March 5, 2007. The Premarket Notification (510[k]) presents data in support of the MicroScan® Synergies plus® Gram-Positive MIC/Combo Panel with vancomycin.
Vancomvcin has been cleared for susceptibility testing via Premarket Notification submissions. The Special Premarket Notification (510{k}) presents support of a request for a device modification, the updating of the product labeling with S. aureus interpretive criteria of (S ≤ 2, 1 = 4 -8, R ≥ 16).
The S. aureus data from the previously cleared vancomycin external evaluation (K060312) was compared to the performance of a CLSI frozen Reference panel utilizing the revised interpretative criteria (S ≤ 2. I = 4 -8. R ≥ 16). Challenge strains were compared to Expected Results determined prior to the evaluation. The Synergies plus Gram-Positive Panel demonstrated acceptable performance with an overall Essential Agreement of 97.6% for vancomycin when compared with the frozen Reference panel.
1
Image /page/1/Picture/0 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three stripes forming its body and wings. The eagle is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Building 66 Silver Spring, MD 20993
OCT 2 3 2009
Ms. Shannon Popson Regulatory Affairs Senior Technical Specialist Siemens Healthcare Diagnostics 2040 Enterprise Blvd West Sacramento, CA 95691
Re: K092919 Trade/Device Name: MicroScan® Synergies plus® Gram - Positive MIC/Combo Panels with Vancomycin (0.25 - 64 mcg/ml) Regulation Number: 21 CFR 866.1640 21 CFR 866.1645 Regulation Name: Antimicrobial Susceptibility Test Powder Fully automated short-term incubation cycle antimicrobial susceptibility system
Regulatory Class: Class II Product Code: LON, JWY Dated: August 24, 2009 Received: September 23, 2009
Dear Ms Popson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
2
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Freddie Lu-Poole, MS
for
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
3
Indication for Use ·
510(k) Number (if known): 《♡오일 |9
Device Name: MicroScan® Synergies plus® Gram-Positive MIC/Combo Panels with Vancomycin (0.25 - 64 mcg/ml)
Indication For Use:
The MicroScan® Synergies plus® Gram-Positive MIC/Combo Panel is used to determine quantitative and/or qualitative antimicrobial agent susceptibility of colonies grown on solid media of rapidly growing aerobic and facultative anaerobic gram-positive staphylococci and enterococci. After inoculation, panels are incubated for 4.5 - 18 hours at 35℃ +/- 1℃, in a WalkAway® SI, or equivalent, and read by the MicroScan® Instrumentation. Additionally, the panels may be incubated in a non-CO2 incubator and the Antimicrobial Susceptibility Testing (AST) portions can be read visually, according to the Package Insert.
This particular submission is for the addition of the antimicrobial vancomycin, at concentrations of 0.25 to 64 ug/ml, to the test panel.
The gram-positive organisms which may be used for vancomycin susceptibility testing in this panel are:
- Enterococcus spp. (e.g., Enterococcus faecalis) .
- Staphylococcus spp. ●
- Staphylococcus aureus (including methicillin-resistant strains) .
- Staphylococcus epidermidis (including methicillin-resistant ● strains)
Prescription Use (21 CFR Part 801 Subpart D) And/Or
Over the Counter Use _ (21 CFR Part 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
Ledalitha Poole
Ofvision Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) K092919
Page 1 of 2